Last updated: May 26, 2026
Executive summary: Arimoclomol citrate sourcing is typically split between (1) API manufacture and (2) formulated drug product supply. Public information that definitively names commercial suppliers for arimoclomol citrate API and finished dosage forms is limited without specifying a market (US/EU/Japan) and a specific reference product. What can be stated from published corporate and regulatory footprints is that arimoclomol citrate is primarily developed and supplied through a small set of program-linked manufacturers, and supply chain diligence is required to map API vs drug product responsibility in each geography.
Who supplies arimoclomol citrate API and drug product?
Featured snippet: Arimoclomol citrate suppliers are typically program-linked contract manufacturers and packaged drug product supply partners tied to the clinical or marketed product, with API sourcing handled separately from formulation and packaging.
API suppliers: how to identify the real manufacturer
For arimoclomol citrate, “supplier” in procurement terms can mean:
- API manufacturer (active ingredient production under GMP)
- API distributor (commercial trading entity)
- Drug product manufacturer (tablet/capsule production, fill-finish if applicable)
- Packager/labeler (secondary packaging and labeling under GMP)
Because procurement and litigation due diligence depend on the exact manufacturing step, the most reliable mapping is through:
- Drug master files (DMFs) and referenced CMC sections in regulatory submissions
- GMP certificates covering the specific dosage form and manufacturing site
- Label/IFU and regulatory listings that identify the manufacturer of record
Drug product suppliers
Drug product supply is usually:
- Manufactured at a separate GMP site from API
- Controlled for packaging configuration (strength, container closure system, labeling language)
- Often aligned to a single global “marketing authorization holder” or program sponsor for a given territory
What companies supply arimoclomol citrate under GMP?
Featured snippet: GMP supply for arimoclomol citrate is held by the limited number of sites used for clinical/regulated manufacture in each territory. Those sites are typically listed in regulatory documentation and on product labels once a marketing authorization is in place.
Common supplier categories used in arimoclomol citrate programs
- Contract development and manufacturing organizations (CDMOs) for solid oral dosage forms
- API manufacturers with capability for chiral salt formation and controlled crystallization (where relevant to citrate salt specs)
- Independent quality release testing labs supporting batch disposition
Which arimoclomol citrate suppliers handle solid oral dosage forms?
Featured snippet: If the marketed form is solid oral, the most common suppliers are GMP tablet/capsule manufacturing sites under a single CMO responsible for formulation, tableting, and packaging operations.
What to verify in vendor qualification
When qualifying arimoclomol citrate suppliers for solid oral dosing, buyer teams typically verify:
- Site GMP coverage for the exact dosage form (tablet vs capsule)
- Analytical package for arimoclomol citrate identity, assay, related substances, and salt/crystal form controls
- Stability data under ICH conditions for the specific strength and container closure system
- Serialization and labeling capability for destination country requirements
How does arimoclomol citrate supply differ by geography (US vs EU)?
Featured snippet: Supply chain responsibility usually differs by territory because local marketing authorization and labeling require local “manufacturer of record” identification even when the API is sourced globally.
US-focused supplier mapping approach
In the US, buyer teams align supplier qualification to:
- FDA regulatory documentation for the specific product
- Any listed manufacturing sites linked to the approved labeling
- Third-party release sites used for commercial batch disposition
EU-focused supplier mapping approach
In the EU, supplier identification is typically reinforced by:
- EMA submission CMC references
- Authorized manufacturing sites and their roles in production and batch release
What are the procurement risks for arimoclomol citrate sourcing?
Featured snippet: The main sourcing risks are site-level manufacturing continuity, analytical method transfer, and salt specification consistency across suppliers.
Risk points buyers flag
- Alternate crystallization or salt form variation changing impurity profile
- Method transfer delays for HPLC/LCMS related substances
- Stability and shelf-life mismatches for different packaging configurations
- Supply interruption from single-site reliance for API or critical intermediates
When do arimoclomol citrate suppliers change (clinical-to-commercial transition)?
Featured snippet: Supplier changes typically track to scale-up and validation milestones, with API and drug product sourcing shifting when a program moves from clinical material to commercial GMP batches.
Timing patterns to watch
- Batch transfer timelines after process validation
- Filing or variation approvals in the destination authority’s CMC lifecycle
- Vendor qualification completion dates for analytics and stability
What patent or exclusivity constraints affect arimoclomol citrate supply?
Featured snippet: Patent and regulatory exclusivity can limit generic or alternative-manufacturer supply, especially for specific process/formulation claims tied to arimoclomol citrate.
Procurement implication
Even if multiple CDMOs can technically produce arimoclomol citrate, legal and licensing constraints may restrict commercial supply of:
- Specific manufacturing processes
- Specific dosage formulations
- Specific manufacturing know-how
How many suppliers exist for arimoclomol citrate API?
Featured snippet: The market typically supports a small supplier set for niche salts and program-linked products, but the exact count depends on which segment is counted (API-only, finished product, or both) and which territory is considered.
Market reality
For molecules with limited commercial footprint, suppliers are often:
- CDMOs engaged by the program sponsor
- Companies qualified for specific regulatory submissions
- Limited to a few validated sites capable of meeting stability and impurity specs
Key Takeaways
- Arimoclomol citrate supply is usually split between API manufacture and drug product manufacturing, often at different GMP sites.
- “Supplier” in procurement must be defined as API vs finished dosage form because the manufacturer of record can differ from the API producer.
- Geography drives who is listed as manufacturer of record and who supplies release-ready batches.
- The practical due diligence focus is site GMP qualification, analytical and salt specification consistency, stability alignment, and continuity risk from single-site dependence.
FAQs
1) Who is the manufacturer of record for arimoclomol citrate in the US or EU?
Manufacturer-of-record identification is tied to the specific marketed product and territory and is typically shown in regulatory submissions and labeling.
2) Can I source arimoclomol citrate API from multiple CDMOs?
Some CDMOs may offer technical manufacture, but commercial supply depends on GMP qualification, analytical capability transfer, and regulatory pathway mapping.
3) What documents should procurement request from an arimoclomol citrate supplier?
Procurement typically requests GMP certificates for the site, COA templates with impurity methods, stability reports, and traceability documentation tied to the intended dosage form configuration.
4) Does arimoclomol citrate supply require salt form controls?
Yes. Buyers typically verify salt specification controls because changes can shift impurity profiles and stability.
5) What drives lead times for arimoclomol citrate batches?
Lead times are driven by API production scheduling, analytical release slotting, stability commitments for the chosen container closure system, and any packaging/labeling configuration constraints for the destination market.
References
- [No sources were provided in the prompt to cite specific suppliers, sites, DMF holders, or regulatory listings for arimoclomol citrate.]
